Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TBITW
ADC Name
wO2024181570A1 ADC2
Synonyms
WO2024181570A1 ADC2
   Click to Show/Hide
Organization
TAIHO PHARMACEUTICAL CO., LTD.
Drug Status
Investigative
Drug-to-Antibody Ratio
2.7
Structure
Antibody Name
Antibody 2
  Antibody Info 
Antigen Name
Syndecan-1 (SDC1)
  Antigen Info 
Payload Name
Mertansine DM4
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
SPDB
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
SPDB-DM4
ADC-specific functional property(2027 Update)
Payload Release Efficiency
Click To Hide/Show 2 ADC-specific functional property Data
Incubation Time 48hr Release 8.29% Reference
[1]
Description
Free Payload Release (%) in Human plasma at 37 °C for 48 h.
Incubation Time 48hr Release 23.96% Reference
[1]
Description
Free Payload Release (%) in Mouse plasma at 37 °C for 48 h.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth lnhibition value (TGl) 
≈ 0
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
≈ 7
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
≈ 70
%
Undisclosed Undisclosed
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
248
ng/mL
CVCL_0237
Pancreatic ductal adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
274
ng/mL
CVCL_0065
T acute lymphoblastic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 0% Positive CD138 expression (CD138+++/++)
Method Description
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
In Vivo Model Capan-1 derived Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 7% Positive CD138 expression (CD138+++/++)
Method Description
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
In Vivo Model Capan-1 derived Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 70% Positive CD138 expression (CD138+++/++)
Method Description
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
In Vivo Model Capan-1 derived Xenograft Model
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 248 ng/mL Positive CD138 expression (CD138+++/++)
Method Description
1000 cells/well of Capan-1 in 96 well, 37 °C for 5 days.
In Vitro Model Pancreatic ductal adenocarcinoma Capan-1 cells CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 274 ng/mL Negative CD138 expression (CD138-)
Method Description
1000 cells/well of Jurkat in 96 well, 37 °C for 5 days.
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
References
Ref 1 Antibody-drug complexes containing anti-CD138 antibodies